|
|
 |
Registry of Lobbyists - Catherine Desjardins
To find further information on a company or organization check the Registry of Joint Stock Companies
|
|
| Registration Number | Status | | | 3032 | Active | | | Initial registration date | Last date of any changes | | 23-October-2023 | 29-April-2024 |
|
Lobbyist's Last Name
Desjardins |
Lobbyist's First Name
Catherine |
Middle Initial
|
|
Business Address of Lobbyist
8401 Trans Canada Highway |
City
St-Laurent |
Province/State
PQ |
Country
CA |
Postal/Zip Code
H4s1z1 |
Telephone
5142464161 |
Fax
|
| |
Business or Firm Name for Lobbyist (if applicable)
AbbVie Corporation |
Registry of Joint Stock Companies Number
abbvie corporation |
Business Address of Lobbyist's Business or Firm
8401 Trans Canada Highway |
City
St-Laurent |
Province/State
PQ |
Country
CA |
Postal/Zip Code
H4s1z1 |
Telephone
5142464161 |
Fax
|
|
| Beneficiary Name |
Beneficiary Type |
|
| Catherine Desjardins |
Subsidiary |
View
|
|
|
|
|
Description of Employer's Business:
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca. |
| |
|
|
|
| Description |
|
| Healthcare policy |
View
|
| AbbVie Corporation engages the Nova Scotia government to advocate for policies that support timely access to AbbVie’s innovative medicines for appropriate patients More specifically, we engage with government to: • Advocate for the value of innovative pharmaceuticals in improving patient outcomes and overall savings to the healthcare system, as well as advancing health security and economic growth. • Identify partnership opportunities with the Government of Nova Scotia, Regional Health Authorities and Universities in clinical research on new and existing treatments and therapies, and the generation of real-world evidence. • Help support health system improvements and healthcare outcomes. • Advocate for pharmaceutical pricing and reimbursement policies that reflect the value of new medicines to patients and the health care system. |
View
|
|
|
|
|
|
No funding from any government or agency
|
|
No private funding related to lobbying activities
|
|
|
|
|
